Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Severine Isabelle Gharbi"'
Autor:
Severine Isabelle Gharbi, Laura A. Pelletier, Alfonso Espada, Jesus Gutiérrez, Sonia Maria Gutiérrez Sanfeliciano, Charles T. Rauch, Maria Patricia Ganado, Carmen Baquero, Elisabet Zapatero, Aiping Zhang, Jordi Benach, Anna-Maria Russell, Leticia Cano, Sandra Gomez, Howard Broughton, Nicholas Pulliam, Carmen Maria Perez, Raquel Torres, Marjoke F. Debets, Alfonso de Dios, Oscar Puig, Mark T. Hilgers, Maria Jose Lallena
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-11 (2022)
Abstract Despite the biological and therapeutic relevance of CDK4/6 for the treatment of HR+, HER2- advanced breast cancer, the detailed mode of action of CDK4/6 inhibitors is not completely understood. Of particular interest, phosphorylation of CDK4
Externí odkaz:
https://doaj.org/article/a4901c8cc1f2445081034949720c4383
Autor:
Severine Isabelle Gharbi, Laura A. Pelletier, Alfonso Espada, Jesus Gutiérrez, Sonia Maria Gutiérrez Sanfeliciano, Charles T. Rauch, Maria Patricia Ganado, Carmen Baquero, Elisabet Zapatero, Aiping Zhang, Jordi Benach, Anna-Maria Russell, Leticia Cano, Sandra Gomez, Howard Broughton, Nicholas Pulliam, Carmen Maria Perez, Raquel Torres, Marjoke F. Debets, Alfonso de Dios, Oscar Puig, Mark T. Hilgers, Maria Jose Lallena
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-2 (2022)
Externí odkaz:
https://doaj.org/article/3b011c3c5bd0459a9b47a137f7b7d6fd
Autor:
Joshua A. Ballard, Timothy Kercher, David Abraham, Ryan Brecht, Nathan A. Brooks, Thomas Buckles, Desta Bume, David Busha, Ernst Peder Cedervall, Kevin Condroski, Kevin Ebata, Severine Isabelle Gharbi, Robert Hazlitt, Tony Morales, Nisha Patel, Jessica Podoll, Kaveri Urkalan, Sandra Gomez Villalain, Shane Walls, Faith Watson, Peiyi Yang, Barbara J. Brandhuber, Steven W. Andrews
Publikováno v:
Molecular Cancer Therapeutics. 20:P141-P141
Alterations in the fibroblast growth factor receptors (FGFRs) have been identified as oncogenic drivers in many human cancers. Specifically, activating FGFR3 gene alterations are found in ~15% of metastatic bladder cancers. One pan-FGFR inhibitor has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::646b0e135391091fa9dfbd075ced65a3
https://doi.org/10.1158/1535-7163.targ-21-p141
https://doi.org/10.1158/1535-7163.targ-21-p141